Pfizer to imitate Abbott’s and J&J’s business model
This article was originally published in Scrip
Executive Summary
Pfizer will split its business into smaller, autonomous units, much like Johnson & Johnson and Abbott Laboratories, as the firm tries to manage its buyout of Wyeth. The company’s CEO told Bloomberg that the strategy would maintain Pfizer’s growth despite its size and dependence on one product.